Media coverage about Sarepta Therapeutics (NASDAQ:SRPT) has trended somewhat positive on Tuesday, AlphaOne reports. The research group, a subsidiary of Accern, scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a coverage optimism score of 0.25 on AlphaOne’s scale. AlphaOne also assigned news coverage about the biotechnology company an impact score of 86 out of 100, meaning that recent press coverage is very likely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have impacted Alpha One Sentiment’s scoring:

Sarepta Therapeutics (NASDAQ:SRPT) traded up 1.3967% during mid-day trading on Tuesday, reaching $31.2099. 1,058,488 shares of the company’s stock were exchanged. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $63.73. The company’s market cap is $1.71 billion. The stock has a 50-day moving average price of $30.58 and a 200 day moving average price of $35.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.62. The firm earned $5.42 million during the quarter, compared to analyst estimates of $4.86 million. The business’s revenue was up 333.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.44) earnings per share. Equities analysts predict that Sarepta Therapeutics will post ($2.50) earnings per share for the current fiscal year.

Several research analysts have recently weighed in on the stock. Vetr raised shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating and set a $34.53 target price on the stock in a research report on Monday, March 20th. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 16th. Cowen and Company reissued an “outperform” rating and issued a $62.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, December 21st. Robert W. Baird reissued a “buy” rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, January 10th. Finally, Leerink Swann reissued a “market perform” rating and issued a $32.00 target price (down from $33.00) on shares of Sarepta Therapeutics in a research report on Wednesday, February 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $56.74.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/04/18/sarepta-therapeutics-srpt-given-news-impact-rating-of-0-25.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.